Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07092566
PHASE3

R.E.C.K vs Exparel in Robotic Nephrectomy

Sponsor: Wake Forest University Health Sciences

View on ClinicalTrials.gov

Summary

The purpose of the study is to evaluate the efficacy of R.E.C.K (ropivacaine epinephrine clonidine ketorolac) vs Exparel during robotic partial and radical nephrectomy in a single institution, prospective, randomized trial. The study will evaluate post operative Numerical Rating Score (NRS) pain scores, post operative pain medication intake (opioids and over-the-counter pain medicines) and length of stay across the two patient cohorts. The findings will help to inform whether the increased cost of Exparel when compared to R.E.C.K is justified.

Official title: Efficacy of Ropivacaine Epinephrine Clonidine Ketorolac (R.E.C.K) vs Exparel in Robotic Nephrectomy: a Randomized, Prospective Trial

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

170

Start Date

2025-11-14

Completion Date

2027-10

Last Updated

2026-01-20

Healthy Volunteers

No

Interventions

DRUG

Ropivacaine HCL

123 mg, intramuscular

DRUG

Exparel

100 mL total dose - Intramuscular (IM), intraoperatively

DRUG

Epinephrine

0.25 mg, intramuscular

DRUG

Clonidine HCL

0.04 mg, intramuscular

DRUG

Ketorolac

15 mg, intramuscular

Locations (1)

Levine Cancer

Charlotte, North Carolina, United States